Article
Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics.
Pharmacogenomics - 1 Apr 2010
Tarr Philip E, Rotger Margalida, Telenti Amalio
Abstract excerpt
HIV-infected individuals may have accelerated atherogenesis and an increased risk for premature coronary artery disease. Dyslipidemia represents a key pro-atherogenic mechanism. In HIV-infected patients, dyslipidemia is typically attributed to the adverse effects of antiretroviral therapy. Nine recent genome-wide association studies have afforded a comprehensive, unbiased inventory of common SNPs at 36 genetic...
Topics
- Anti-HIV Agents
- Coronary Artery Disease
- Diabetes Mellitus
- Dyslipidemias
- Genome, Human
- HIV Infections
- Humans
- Lipids
- Pharmacogenetics
- Polymorphism, Single Nucleotide
